Poseida Therapeutics is at the forefront of developing innovative genetic engineering technologies aimed at transforming the treatment landscape for life-threatening cancers and genetic diseases. The company utilizes a suite of proprietary platforms, including the non-viral piggyBac® DNA Delivery System and the Cas-CLOVER™ Site-Specific Gene Editing System. The piggyBac system is designed to insert large genetic payloads into the genome, allowing for stable integration and durable expression of therapeutic genes. This platform is particularly effective in modifying T cells, enriching them for an early memory phenotype, which is crucial for long-lasting anti-tumor responses. Meanwhile, the Cas-CLOVER system enables precise gene editing with minimal off-target effects, facilitating accurate modifications in various cell types, including T cells, which are essential for effective CAR-T therapies.

Poseida's focus on allogeneic CAR-T therapies represents a significant shift from traditional autologous approaches, where T cells are sourced from individual patients. By utilizing healthy donor-derived T cells, Poseida aims to create off-the-shelf treatments that can be readily available for patients. Their innovative gene editing techniques, such as disrupting T cell receptor beta and human leukocyte antigens (HLA), are designed to enhance the safety and efficacy of these therapies by reducing the risk of immune reactions like graft-versus-host disease (GvHD). The combination of these advanced technologies positions Poseida Therapeutics as a leader in the development of next-generation cell and gene therapies, with the potential to provide functional cures for a range of cancers and rare genetic disorders.

United States

Our mission at Poseida Therapeutics is to create cell and gene therapies with the capacity to cure. We are developing novel products using our broad gene engineering platform technologies, with the goal of bringing new and better treatments to patients with serious diseases, first in the blood-based cancer Multiple Myeloma and next in solid tumors like prostate cancer.

Cancer

Genetic Diseases

Liver Diseases

Poseida Therapeutics

Multiple myeloma

P-BCMA-101 targets cells that express B cell maturation antigen, or BCMA, which is expressed on essentially all multiple myeloma cells. P-BCMA-101 is engineered with Poseida's non-viral piggyBac® DNA Modification System, resulting in a high percentage of T stem cell memory cells. P-BCMA-101 is composed primarily of Tscm, a very young subset of T cells that are long-lived, self-renewing and multipotent, with the capacity to reconstitute the entire spectrum of T cell subsets, including T effector cells. They also survive for decades, and potentially for entire lifespans, with non-CAR-Tscm cells normally providing lifelong T cell immunity against some infectious agents.
CAR T

P-BCMA-ALLO1 (CAR-T)

Breast cancer

Ovarian cancer

Solid tumor/s

This is an allogeneic CAR-T product candidate in development for multiple solid tumor indications. We believe P-MUC1C-ALLO1 has the potential to treat a wide range of solid tumors derived from epithelial cells, such as breast, colorectal, lung, ovarian, pancreatic, and renal cancers, as well as other cancers expressing a cancer-specific form of the Mucin 1 protein, or MUC1-C. We have designed P-MUC1C-ALLO1 to be fully allogeneic, with genetic edits to eliminate or reduce both host-vs-graft and graft-vs-host alloreactivity. We have demonstrated the elimination of tumor cells to undetectable levels in two preclinical models of breast cancer and a preclinical model of ovarian cancer.
CAR T

P-MUC1C-ALLO1

B-cell malignancies

P-CD19CD20-ALLO1 is an allogeneic CAR-T cell therapy product candidate being developed for relapsed or refractory B-cell malignancies in partnership with Roche. P-CD19CD20-ALLO1 expresses two fully functional CAR molecules to target cells that express either CD19 or CD20. The dual targeting approach employed in P-CD19CD20-ALLO1 aims to overcome the antigen escape limitations of CD19-only targeted CAR-T therapies by simultaneously targeting both CD19 and CD20.&nbsp; In addition to the dual targeting, P-CD19CD20-ALLO1 uses a novel CD19 binder that showed greater potency in in vivo preclinical models when compared to the canonical FMC63 Single-chain variable fragment (scFv) binder. &nbsp;P-CD19CD20-ALLO1 is an off-the-shelf CAR-T therapy for which patients do not have to undergo apheresis and wait for the cells to be manufactured, which can potentially overcome the limitation of autologous CAR-T therapies associated with significant manufacturing times. P-CD19CD20-ALLO1 will be studied in multiple B-cell malignancies.

P-CD19CD20-ALLO1

Castration-resistant prostate cancer

Prostate cancer

Our autologous CAR-T product candidates are developed using our piggyBac DNA Modification System to modify a patient’s own cells to treat their disease. We intend to leverage what we learn from our autologous programs to inform and improve our allogeneic programs.
Autologous CAR-T product candidate targeting prostate-specific membrane antigen, or PSMA, being developed to treat patients with mCRPC.
This is our solid tumor autologous CAR-T product candidate targeting prostate-specific membrane antigen, or PSMA, being developed to treat patients with metastatic castrate resistant prostate cancer, or&nbsp;mCRPC.
Our proprietary piggyBac DNA Modification system is at the heart of our novel approach to treatments. With its unique design, piggyBac efficiently delivers extensive genetic cargo into cells, creating solutions far beyond earlier-generation therapies.
CAR T

Poseida Therapeutics

Company Details